PRODUCT NAME

Bulk anti-Human CD40 antibody (G28.5) [ICH1156]

SPECIES REACTIVITY

Human

HOST

Mouse

SPECIFICITY

Clone G28.5 recognizes an epitope on human CD40

PURIFICATION METHOD

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

ANTIGEN DISTRIBUTION

CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors.

IMMUNOGEN

CONCENTRATION

FORMULATION

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free

PURITY

>95% by SDS-PAGE and HPLC

ENDOTOXIN

≤ 1.0 EU/mg as determined by the LAL method

AGGRIGATION

Aggregation level ≤ 5%

STORAGE CONDITION

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

TARGET

CD40

CLONE

G28.5

SYNONYMS

BACKGROUND

CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.

UNIPROT

P27512

PATHOGEN TEST

APPLICATIONS

Functional Assays, Flow Cytometry

APPLICATION NOTES

Each investigator should determine their own optimal working dilution for specific applications.

USAGE

Products are for research use only. Not for use in diagnostic or therapeutic procedures.